Pfizer COVID-19 vaccine approved for use in European Union

Read us | Listen to us | Watch us |Events| Subscribe | Our Social Media|


Afrikaans Afrikaans Albanian Albanian Amharic Amharic Arabic Arabic Armenian Armenian Azerbaijani Azerbaijani Basque Basque Belarusian Belarusian Bengali Bengali Bosnian Bosnian Bulgarian Bulgarian Cebuano Cebuano Chichewa Chichewa Chinese (Simplified) Chinese (Simplified) Corsican Corsican Croatian Croatian Czech Czech Dutch Dutch English English Esperanto Esperanto Estonian Estonian Filipino Filipino Finnish Finnish French French Frisian Frisian Galician Galician Georgian Georgian German German Greek Greek Gujarati Gujarati Haitian Creole Haitian Creole Hausa Hausa Hawaiian Hawaiian Hebrew Hebrew Hindi Hindi Hmong Hmong Hungarian Hungarian Icelandic Icelandic Igbo Igbo Indonesian Indonesian Italian Italian Japanese Japanese Javanese Javanese Kannada Kannada Kazakh Kazakh Khmer Khmer Korean Korean Kurdish (Kurmanji) Kurdish (Kurmanji) Kyrgyz Kyrgyz Lao Lao Latin Latin Latvian Latvian Lithuanian Lithuanian Luxembourgish Luxembourgish Macedonian Macedonian Malagasy Malagasy Malay Malay Malayalam Malayalam Maltese Maltese Maori Maori Marathi Marathi Mongolian Mongolian Myanmar (Burmese) Myanmar (Burmese) Nepali Nepali Norwegian Norwegian Pashto Pashto Persian Persian Polish Polish Portuguese Portuguese Punjabi Punjabi Romanian Romanian Russian Russian Samoan Samoan Scottish Gaelic Scottish Gaelic Serbian Serbian Sesotho Sesotho Shona Shona Sindhi Sindhi Sinhala Sinhala Slovak Slovak Slovenian Slovenian Somali Somali Spanish Spanish Sudanese Sudanese Swahili Swahili Swedish Swedish Tajik Tajik Tamil Tamil Thai Thai Turkish Turkish Ukrainian Ukrainian Urdu Urdu Uzbek Uzbek Vietnamese Vietnamese Xhosa Xhosa Yiddish Yiddish Zulu Zulu
Pfizer COVID-19 vaccine approved for use in European Union
covid vaccine allergic reaction
Written by Harry S. Johnson

On Monday, the European Medicines Agency (EMA) announced that it is recommending the Pfizer/BioNTech COVID-19 vaccine be granted authorization for use in the European Union for people over the age of 16.

The agency’s decision is a major step in the continent’s efforts to tackle COVID-19.

A statement released by EMA claims that the organization has undertaken “rigorous” evaluation of the vaccine and is satisfied by the robustness of the data provided on quality, safety, and efficacy.

“Today’s positive news is an important step forward in our fight against this pandemic, which has caused suffering and hardship for so many,” said Emer Cooke, executive director of EMA.

“We have achieved this milestone thanks to the dedication of scientists, doctors, developers and trial volunteers as well as many experts from all EU Member States.”

The press release said that Pfizer trial data showed the jab to be 95 percent effective in reducing symptomatic Covid-19 cases, adding that the high level of efficacy was maintained across genders, racial and ethnic groups.

“Our work does not stop here. We will continue to collect and analyse data on the safety and effectiveness of this vaccine to protect people taking the vaccine in the EU,” Cooke noted.

The decision to approve the vaccine will now be handed over to the European Commission (EC).

EC President Ursula von der Leyen said on Monday that the commission would act quickly following the EMA’s recommendation.

“Now we will act fast. I expect a European Commission decision by this evening,” she wrote on Twitter.

Print Friendly, PDF & Email
>